<DOC>
	<DOCNO>NCT02444364</DOCNO>
	<brief_summary>Participants person Type 2 Diabetes likely increase risk bone fracture . The investigator believe medication enhance bone turnover . The investigator use DXA measurement evaluate bone density subject take medication .</brief_summary>
	<brief_title>Effects DPP-4 Inhibition Calcium Bone Metabolism Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Type 2 Diabetes Mellitus ( T2DM ) associate increase risk bone fracture even decrease bone density via DXA measurement . This appear primarily relate impaired bone quality abnormal bone architecture . Although exact pathophysiologic mechanism remain unclear , low bone turnover consider one key defect . Emerging evidence suggest dipeptidyl peptidase ( DPP ) inhibition associate improved bone quality reduction fracture risk . While animal study show improvement bone mineral density trabecular architecture sitagliptin treatment , study humans yet undertake . We propose extend animal study pilot clinical trial seek use serum marker bone turn-over calcaneal quantitative ultrasound evaluate effect DPP-4 inhibition bone metabolism . Our hypothesis DPP-4 inhibition sitagliptin enhance bone turn quality person T2DM . This project project seek examine impact six month therapy sitagliptin , DPP-4 inhibitor , bone metabolism bone quality subject T2DM . The propose study intend pilot investigation provide preliminary data submission definitive national grant proposal large patient population , blind randomize control design high resolution CT image lumbar spine .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Type 2 diabetes mellitus . 2 . Hemoglobin A1c &gt; 6.5 % &lt; 10 % . 3 . Estimated GFR great 60 mL per minute per meter square . 4 . Between 18 70 year age . 5 . On oral antihyperglycemic agent stable dose least last 2 month . 6 . Females : minimum two year postmenopausal , surgically sterile , use acceptable contraceptive regimen ( OCP , IUD , double barrier , DepoProvera subcutaneous progestin implant ) negative urine pregnancy test trial start . 1 . Pregnancy , breast feeding planning pregnancy study period 2 . Any medical condition expect terminal within one year 3 . Active mental illness condition opinion investigator would prevent informed consent adherence study protocol 4 . Use PPAR agonist within three month prior enrollment 5 . Daily insulin use 6 . Vitamin D level &lt; 20 7 . Allergy intolerance sitagliptin DPP4 inhibitor 8 . Use DPP4 inhibitor GLP1 analog within three month prior enrollment 9 . Significant alcohol use define &gt; 3 standard serving alcohol per day men &gt; 2 woman 10 . History bariatric surgery last 3 year plan bariatric surgery study period 11 . Receipt another study drug within 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>bone loss</keyword>
	<keyword>Bone Density</keyword>
</DOC>